SAN DIEGO--(BUSINESS WIRE)--Jul. 31, 2017--
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, announced today that it will present at the 37th
Annual Canaccord Genuity Growth Conference, to be held at the
InterContinental Boston hotel in Boston, Massachusetts on Wednesday,
August 9, 2017.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present that day at 11:30 a.m.
Eastern time (8:30 a.m. Pacific time) with a question and answer session
scheduled immediately following the presentation. During the
presentation, the company will discuss business and financial
developments and trends. The company's statements may contain or
constitute material information that has not been previously disclosed.
A live webcast and audio archive of each presentation will be available
via the Investor Relations section of the company’s Web site at http://ir.quidel.com
or by clicking on the following link:
Participants should allow approximately five to ten minutes prior to the
presentation's start time to visit the site and download any streaming
media software needed to listen to the Internet webcast. A replay of the
webcast will also be available on the company’s Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct
Detection, Thyretain® and InflammaDry® leading brand names, as well as
under the new Solana®, AmpliVue® and Lyra® molecular
diagnostic brands, Quidel's products aid in the detection and diagnosis
of many critical diseases and conditions, including, among others, influenza,
syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal
occult blood. Quidel's research and development engine is also
developing a continuum of diagnostic solutions from advanced
lateral-flow and direct fluorescent antibody to molecular diagnostic
tests to further improve the quality of healthcare in physicians'
offices and hospital and reference laboratories. For more information
about Quidel's comprehensive product portfolio, visit quidel.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170731006088/en/
Source: Quidel Corporation
Media and Investors